SCHEMBL580336

SCHEMBL580336

CN(C(=O)O)C(=O)c1cc(-c2cccnc2Oc2ccc(N)cc2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 10/20 0.42
FEN1 P39748 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580379 0.87 PDE10A (0.40) PDE10AFEN1
SCHEMBL580894 0.83 PDE10A (0.46) PDE10AFEN1
SCHEMBL2456284 0.77 PDE10A (0.56) PDE10AFEN1
SCHEMBL14878663 0.75 PDE10A (0.58) PDE10AFEN1
SCHEMBL587790 0.74 PDE10A (0.55) PDE10A
SCHEMBL12238435 0.74 FEN1 (0.44) PDE10AFEN1
SCHEMBL2455636 0.73 PDE10A (0.58) PDE10AFEN1
SCHEMBL7904646 0.73 NCOA1 (0.58) PDE10AFEN1
SCHEMBL581393 0.72 PDE10A (0.56) PDE10AFEN1
SCHEMBL14878634 0.71 PDE10A (0.60) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
EP-2418209-A1 Aurora kinase modulators and method of use Amgen Inc. (US) 2012-02-15 EP disclosed
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AMGEN INC. (US) 2011-10-27 US disclosed
US-8022221-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-09-20 US disclosed
US-7560551-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-07-14 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, AURKB PDE10A 3747/4885FEN1 3224/4885
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 PDE10A 4053/4885FEN1 3063/4885
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AURKC, AURKA, AURKB PDE10A 3747/4885FEN1 3224/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB PDE10A 3747/4885FEN1 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.